Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background: The opioid use disorder is an international public health problem. Over the past 20 years it has been the subject of numerous publications concerning patients treated for chronic pain other than cancer-related. Patients with cancer-related pain are also at risk of opioid use disorder. The primary objective of this literature review was to determine the prevalence of opioid use disorder in patients with cancer-related chronic pain. Its secondary objective was to identify the characteristics of these opioid users. Methods: This is a literature review of studies published over the last twenty years, from 1 January 2000 to 31 December 2020 identified by searching the three main medical databases: Pubmed, Cochrane, and Embase. A meta-analysis took account of between and within-study variability with the use of random-effects models estimated by the DerSimonian and Laird method. Results: The prevalence of opioid use disorder was 8% (1–20%) and of the risk of use disorder was 23.5% (19.5–27.8%) with I2 values of 97.8% and 88.7%, respectively. Conclusions: Further studies are now needed on the prevalence of opioid use disorder in patients treated for cancer-related chronic pain. A screening scale adapted to this patient population is urgently needed.

Details

Title
Prevalence of Opioid Use Disorder among Patients with Cancer-Related Pain: A Systematic Review
Author
Preux, Céline 1 ; Bertin, Marion 1 ; Tarot, Andréa 1 ; Authier, Nicolas 2 ; Pinol, Nathalie 3 ; Brugnon, David 1 ; Pereira, Bruno 4   VIAFID ORCID Logo  ; Guastella, Virginie 5   VIAFID ORCID Logo 

 Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; [email protected] (C.P.); [email protected] (M.B.); [email protected] (A.T.); [email protected] (D.B.) 
 Neuro-Dol, Service Pharmacologie Médicale, Centres d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63001 Clermont-Ferrand, France; [email protected]; Institut Analgésia, Faculté de Médecine, BP38, F-63001 Clermont-Ferrand, France; Observatoire Français des Médicaments Antalgiques/French Monitoring Centre for Analgesic Drugs, Université Clermont-Ferrand, F-63001 Clermont-Ferrand, France 
 Centre de Documentation et Recherche de la Faculté de Médecine, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63000 Clermont-Ferrand, France; [email protected] 
 Unité de Biostatistiques, Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; [email protected] 
 Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; [email protected] (C.P.); [email protected] (M.B.); [email protected] (A.T.); [email protected] (D.B.); Neuro-Dol, Service Pharmacologie Médicale, Centres d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63001 Clermont-Ferrand, France; [email protected] 
First page
1594
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2642415729
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.